PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Bluebee and MediSapiens form partnership

Bluebee, a provider of high-performance genomics analysis and storage solutions, and MediSapiens, a biomedical big data curation, management and interpretation company, have formed a partnership to provide customers with analytical solutions for next generation sequencing data.

 
Sequencing technology is maturing and being optimised for performance, while becoming increasingly affordable. This has opened an era of reliable and foreseeable quality data growth, which demands high computational resources and data storage capabilities to be combined with best in class data interpretation tools.
 
MediSapiens’ Explorer Platform is now integrated with the Bluebee platform, offering researchers and clinicians the ability to efficiently curate, analyse, store, interpret and securely share data and findings with colleagues, and use this data efficiently in personalised medicine initiatives, drug development and cohort or population research. The result is a seamlessly combined workflow, from raw sequencing reads to endpoint analyses.
 
“With the combination of Bluebee’s private cloud based robust and scalable platform for high-speed, configurable data analysis and Explorer Platform’s capabilities in data curation, management and interpretation, scientists and clinicians now have a comprehensive integrated solution that will enhance the development of new diagnostics in the research lab and enable improved therapeutic decisions in a clinical setting,” says Hans Cobben, CEO of Bluebee.
 
“For several years, MediSapiens has developed various data interpretation solutions and digital offerings based on its Explorer Platform. Bluebee’s unique capabilities in optimized and secure genomics pipelines fully complement MediSapiens’ integrated biomedical data solutions. This partnership enables us to offer world-class end-to-end solutions for customers working with NGS and offer convenient and powerful tools for pharmaceutical and diagnostic development as well as translational, biobank, cohort and population research,” says Sami Kilpinen, CEO of MediSapiens.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured

Blackstone Private Equity